9.21 -0.09 (-0.97%) | 05-08 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 11.2 | 1-year : | 13.08 |
Resists | First : | 9.59 | Second : | 11.2 |
Pivot price | 9.05 | |||
Supports | First : | 8.61 | Second : | 8.01 |
MAs | MA(5) : | 9.18 | MA(20) : | 8.91 |
MA(100) : | 8.36 | MA(250) : | 7.35 | |
MACD | MACD : | 0.1 | Signal : | 0.1 |
%K %D | K(14,3) : | 73.8 | D(3) : | 77.7 |
RSI | RSI(14): 58.5 | |||
52-week | High : | 9.59 | Low : | 4.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TLIS ] has closed below upper band by 25.4%. Bollinger Bands are 47.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 9.6 - 9.65 | 9.65 - 9.68 |
Low: | 8.94 - 9 | 9 - 9.04 |
Close: | 9.12 - 9.21 | 9.21 - 9.28 |
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Wed, 08 May 2024
TLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024 - MSN
Wed, 08 May 2024
Talis: Q1 Earnings Snapshot | National News | clintonherald.com - Clinton Herald
Sat, 04 May 2024
(TLIS) Investment Analysis and Advice - Stock Traders Daily
Sat, 27 Apr 2024
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Talis, TaskUs, and RTR on Behalf of Long-Term ... - GlobeNewswire
Wed, 21 Jun 2023
TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term ... - Business Wire
Tue, 10 May 2022
Talis Biomedical Announces First Quarter 2022 Financial Results - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 0 (M) |
Shares Float | 2 (M) |
Held by Insiders | 1.01e+006 (%) |
Held by Institutions | 8.3 (%) |
Shares Short | 14 (K) |
Shares Short P.Month | 0 (K) |
EPS | -6.328e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -7 % |
Return on Assets (ttm) | 413.3 % |
Return on Equity (ttm) | -30.4 % |
Qtrly Rev. Growth | 2.13e+006 % |
Gross Profit (p.s.) | -13.86 |
Sales Per Share | -36.4 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -34.2 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -53 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.26 |
Price to Cash Flow | 0.42 |
Dividend | 0 |
Forward Dividend | 12260 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |